Delving into the Latest Updates on Ingavirin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

IMIDAZOLYL ETHANAMIDE PENTANDIOIC ACID, Vitaglutam

+ [2]

Target-

Action

inhibitors, stimulants

Mechanism

Apoptosis inhibitors, Granulocytes stimulants, Haematopoiesis stimulants

+ [1]

Therapeutic Areas

Infectious DiseasesHemic and Lymphatic DiseasesRespiratory Diseases

Active Indication

Virus DiseasesInfluenza, HumanNeutropenia

Inactive Indication

Acute Radiation SyndromeAcute respiratory infectionsBone marrow depression+ [6]

Originator Organization

Valenta Pharmaceuticals JSC

Active Organization

Valenta Pharmaceuticals JSC

Inactive Organization

Myelo Therapeutics GmbHBausch Health Americas, Inc.

License Organization-

Drug Highest PhaseApproved

First Approval Date

Russia (01 Jan 2009),

Influenza, HumanNeutropenia

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC10H15N3O3

InChIKeyKZIMLUFVKJLCCH-UHFFFAOYSA-N

CAS Registry219694-63-0

The primary objective of this study is to investigate the efficacy of Ingavirin®, 90 mg capsules in achieving clinical improvement of novel coronavirus disease (COVID-19) symptoms. A secondary goal of this study is to evaluate the safety of Ingavirin®, 90 mg capsules in patients with COVID-19 infection.

Start Date06 Oct 2021

Sponsor / Collaborator

Valenta Pharmaceuticals JSC

NCT05269290

/ CompletedPhase 3

A Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children Aged 6 Months to 2 Years With Influenza and Other Acute Respiratory Viral Infections Against Standard Therapy

The study is planned to evaluate the therapeutic efficacy and safety of Ingavirin®, syrup, 30 mg/5 ml, in the treatment of influenza or other acute respiratory infections in children from 6 months to 2 years compared with placebo.

Start Date23 Sep 2021

Sponsor / Collaborator

Valenta Pharmaceuticals JSC

100 Clinical Results associated with Ingavirin

Login to view more data

100 Translational Medicine associated with Ingavirin

Login to view more data

100 Patents (Medical) associated with Ingavirin

Login to view more data

80

Literatures (Medical) associated with Ingavirin

02 Jan 2025·International Journal of Radiation Biology

IEPA, a novel radiation countermeasure, alleviates acute radiation syndrome in rodents

Article

Author: Asang, Corinna ; Fish, Brian L. ; Bähr, Stella ; Munjal Mehta, Srishti ; Gasperetti, Tracy ; Czajkowski, Maciej T. ; Eibl, Michael ; Wesolowski, Radoslaw ; Orschell, Christie M. ; Himburg, Heather A. ; Pleimes, Dirk ; Singh, Nikita

Repurposing therapeutic agents with existing clinical data is a common strategy for developing radiation countermeasures. IEPA (imidazolyl ethanamide pentandioic acid) is an orally bioavailable small molecule pseudopeptide with myeloprotective properties, a good clinical safety profile, and stable chemical characteristics facilitating stockpiling. Here, we evaluated IEPA's radiomitigative efficacy in the hematopoietic subsyndrome of acute radiation syndrome (H-ARS) using total-body irradiation (TBI) models in C57BL/6J mice and WAG/RijCmcr rats, applying various posology schemes and introducing syringe feeding of the IEPA formulation in the pudding. Additionally, we assessed IEPA in the delayed effects of acute radiation exposure (DEARE) model after partial-body irradiation (PBI) in WAG/RijCmcr rats. Endpoints included survival, body weight, hematology, and pulmonary parameters, depending on the model. Results from mouse and rat TBI models demonstrated survival improvements with repeated IEPA dosing at 10 mg/kg, with the largest benefits observed in the bi-daily (BID) treatment over the 30-day ARS phase in female rats. Survival across PBI-DEARE subsyndromes was comparable between IEPA and vehicle groups, though IEPA improved pulmonary parameters in female rats during the lung-DEARE phase. Sex-related differences in response to irradiation and IEPA were noted, with females showing a survival advantage. IEPA treatment is compatible with Neulasta® (Pegfilgrastim; PEG-G-CSF); adequately powered studies are needed to confirm the trend toward improved survival over standard care alone. IEPA is a promising development candidate as a medical countermeasure against the effects of acute radiation syndrome. Further confirmatory studies in small and large animal models should validate the robustness and translatability of preliminary rodent data on IEPA's radiomitigative efficacy.

01 Dec 2023·Molecular Diversity

Insight into the Hantaan virus RNA-dependent RNA polymerase inhibition using in-silico approaches

Article

Author: Sharaf, Mohamed ; Abdalla, Mohnad ; Badshah, Syed Lal ; Faisal, Shah

The Hantaan virus (HTN) is a member of the hantaviridae family. It is a segmented type, negative-strand virus (sNSVs). It causes hemorrhagic fever with renal syndrome, which includes fever, vascular hemorrhage, and renal failure. This illness is one of the most serious hemorrhagic diseases in the world, and it is a major public health concern due to its high mortality rate. The Hantaan virus RNA-dependent RNA polymerase complex (RdRp) is involved in viral RNA transcription and replication for the survival and transmission of this virus. Therefore, it is a primary target for antiviral drug development. Interference with the endonucleolytic "cap-snatching" reaction by the HTN virus RdRp endonuclease domain is a particularly appealing approach for drug discovery against this virus. This RdRp endonuclease domain of the HTN virus has a metal-dependent catalytic activity. We targeted this metal-dependent enzymatic activity to identify inhibitors that can bind and disrupt this endonuclease enzyme activity using in-silico approaches i.e., molecular docking, molecular dynamics simulation, predicted absorption, distribution, metabolism, excretion, toxicity (ADMET) and drug-likeness studies. The docking studies showed that peramivir, and ingavirin compounds can effectively bind with the manganese ions and engage with other active site residues of this protein. Molecular simulations also showed stable binding of these ligands with the active site of HTN RdRp. Simulation analysis showed that they were in constant contact with the active site manganese ions and amino acid residues of the HTN virus endonuclease domain. This study will help in better understanding the HTN and related viruses.

01 Jul 2022·Pharmacoepidemiology and Drug Safety

COVID‐19 pharmacotherapy utilization patterns during pregnancy: International Registry of Coronavirus Exposure in Pregnancy

Article

Author: Wyszynski, Diego F. ; Smith, Louisa H. ; Hernandez‐Diaz, Sonia ; Westhoff, Whitney J.

AbstractPurposeWomen infected with SARS‐CoV‐2 during pregnancy are at increased risk of developing severe illness and experience a higher rate of preterm births than pregnant women who are not infected. The use of innovative or repurposed therapies to treat COVID‐19 patients is widespread; however, there are very limited data regarding the patterns of use and safety profile of most of these therapeutics in pregnant women. We assessed the patterns of use of COVID‐19 therapeutics during pregnancy using data from the International Registry of Coronavirus in Pregnancy (IRCEP).MethodsThe IRCEP is an international observational cohort study intended to assess the risk of major obstetric and neonatal outcomes among pregnant women with COVID‐19. Women enrolled while pregnant or within 6 months after end of pregnancy. Follow‐up for women enrolled while pregnant includes monthly online questionnaires throughout the pregnancy and, for live births, through the infant's first 90 days of life. Participants provide information on demographic characteristics, health history, COVID‐19 tests and symptoms, medications, and obstetric and neonatal outcomes.ResultsA total of 5780 women with COVID‐19 during pregnancy were identified from the IRCEP. Severity of COVID‐19 was classified in 372 of them as severe, 3053 moderate, and 2355 mild. The most frequently reported COVID‐19 therapies, other than analgesics, included azithromycin (12.8%), steroids (3.5%), interferon (2.4%), oseltamivir (2.1%), chloroquine/hydroxychloroquine (1.7%), anticoagulants (2.0%), antibodies (0.9%), and remdesivir (0.3%). Most drugs were preferentially used for severe cases. Patterns of use varied by country.ConclusionsIRCEP participants reported use of therapeutics for COVID‐19 during pregnancy for which there is little safety information. Findings on COVID‐19 pharmacotherapy utilization patterns can guide future studies examining the safety of COVID‐19 therapies during pregnancy.

100 Deals associated with Ingavirin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J05AX	DB11944

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Virus Diseases	Russia	Valenta Pharmaceuticals JSC	17 Jul 2014
Influenza, Human	Russia	-	01 Jan 2009
Neutropenia	Russia	-	01 Jan 2009

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Discovery	Russia	Valenta Pharmaceuticals JSC	06 Oct 2021
Bone marrow depression	Discovery	Germany	Myelo Therapeutics GmbH	01 Mar 2016
Breast Cancer	Discovery	Germany	Myelo Therapeutics GmbH	01 Mar 2016
Cervical Intraepithelial Neoplasia	Discovery	Germany	Myelo Therapeutics GmbH	01 Mar 2016
Chemotherapy-Induced Febrile Neutropenia	Discovery	Germany	Myelo Therapeutics GmbH	01 Mar 2016
Acute respiratory infections	Discovery	Russia	Valenta Pharmaceuticals JSC	03 Oct 2010
Common Cold	Discovery	Russia	Bausch Health Americas, Inc.	03 Oct 2010
Common Cold	Discovery	Russia	Valenta Pharmaceuticals JSC	03 Oct 2010
Influenza, Human	Discovery	Russia	Valenta Pharmaceuticals JSC	03 Oct 2010
Viral respiratory infection	Discovery	Russia	Valenta Pharmaceuticals JSC	03 Oct 2010

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2020	Phase 2	Chemotherapy-induced myelosuppression	-	IEPA	(ybykxvujki) = reduced rbuvwlltsg (dsuhqwoizx ) View more	-	25 May 2020
				IEPA (Control)
NCT02692742 (ASCO 12019 \| ASCO 22019) Manual	Phase 2	Breast Cancer	130	Myelo001	ohmecomumx(lnctjkxvjd) = wwtodlmhhj dwvqwbgceo (xbnkqgnfzy, 12.6 - 14.5) View more	Positive	31 May 2019
				placebo	ohmecomumx(lnctjkxvjd) = tglkvgujlv dwvqwbgceo (xbnkqgnfzy, 13.0 - 14.9) View more